Skip to main content

Table 1 Clinical, demographic, and sample characteristics of pwCF (n = 16) on/off ETI therapy (n = 7/9)

From: Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy

Subject ID

ETI

Days on ETI

Period (days) between the first sample and ETI

Samples collected

BMI

Gender

ppFEV1 PP (%)

FVC PP (%)

Pathogen cultures

(Sputum)

001

No

 

104

18.9

F

54.4

73.8

002

No

 

36

27.5

M

54.8

73.1

003

No

 

114

23.0

M

38.7

48.3

Pa, Sa

004

No

 

75

20.6

F

52.9

63.4

Pa, Ac

005

No

 

190

29.0

M

69.6

91.1

Steno

006

No

 

90

18.5

F

52.0

78.4

007

No

 

17

30.2

F

50.0

60.0

Pa, Sa, Ac, Strep

008

No

 

20

21.5

F

52.0

70.0

Pa, Sa

009

No

 

15

22.1

M

40.0

66.0

Pa

010

Yes

537

277

18

27.3

F

111.0

114.0

Pa, Sa

011

Yes

286

163

40

27.9

M

79.0

100.0

Pa, Sa, Steno, Strep

012

Yes

454

226

20

20.2

F

67.0

84.0

Pa, Sa, Strep

013

Yes

453

345

13

23.3

F

72.0

75.0

Pa, Sa, Bc,

014

Yes

227

103

35

20.7

F

53.0

Bc

015

Yes

426

326

15

22.4

F

52.0

70.0

Pa

016

Yes

377

210

21

23.2

F

101.0

107.0

Pa, Sa

  1. Subjects id’s information (001-006) was obtained from [18]. ETI treatment status as well as the time (days) on treatment since started until the last sample collection, body mass index (BMI), gender, highest predicted lung function (ppFEV1 and FVC), and pathogen cultures within sputum are presented. Pathogen results are abbreviated as follows: Pseudomonas aeruginosa (Pa), Staphylococcus aureus (Sa), Burkholderia cepacia (Bc), Achromobacter sp. (Ac), Stenotrophomonas sp. (Steno) and Streptococcus sp. (Strep). The subject’s IDs were decoded as serial numbers to keep the anonymity and privacy of participants.